Search
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release.[A253597] … Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.
Lumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[L4269] It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation … Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnPiperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism. … Upon entry into the systemic circulation, the drug is partly oxidized and partly eliminated as an unchanged compound.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawn[A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … [A262839] In 1960 and 2000, the FDA approved eflornithine under the brand names ORNIDYL and VANIQUA for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Categories: Corticotropin-releasing Factor Type 1 Receptor AntagonistPhylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigational[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity … [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]
Synonyms: 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinoneLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.[A260286] … [A260286] Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012.
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalBy inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. … [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalIt is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of … tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase.